Todas las investigaciones
ReclutamientoFASE2INTERVENCIONISTA

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

This study is looking at a new inhaled medicine called ensifentrine for people who have non-cystic fibrosis bronchiectasis, a long-term lung condition. We want to find out if this medicine, delivered through a nebulizer twice a day, can help reduce breathing flare-ups, ease symptoms, and improve overall quality of life. Some participants will receive the active medicine, while others will receive a placebo (a dummy medicine with no active ingredients). This helps us understand the true effects of ensifentrine. The study will last for at least 24 weeks, comparing the new medicine to standard care. Your participation could help us learn more about treating this condition.

De un vistazo

Estado
Reclutamiento
Fase
FASE2
Patrocinador
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Objetivo de inscripción
284
Inicio
11 Sep 2024
Estimación de finalización
24 Sep 2027

¿De qué trata este estudio?

You're looking at information about a research study for a lung condition called non-cystic fibrosis bronchiectasis. This condition means your airways are wider than they should be, making it harder to clear mucus and leading to infections and breathing difficulties. This study is testing a new medicine called ensifentrine to see if it can help people manage their condition better.

The main aim is to find out if taking ensifentrine regularly, using a device called a nebulizer, can reduce flare-ups (when your symptoms suddenly get worse and you might need antibiotics). We also want to see if it improves how you feel day-to-day, your breathing, and your overall quality of life. This is a "Phase II" study, which means it's an important step in checking if the medicine is safe and if it works as expected before it can be studied in larger groups of people.

To make sure the results are fair and accurate, some people in the study will receive ensifentrine, while others will receive a placebo (a dummy medicine that looks and feels the same but has no active drug). Neither you nor the study team will know who is getting which, and you'll continue to receive your usual medical care alongside the study treatment. This combination helps us understand exactly what impact ensifentrine might have.

Puntos clave

  • Tests a new inhaled medicine (ensifentrine) for non-cystic fibrosis bronchiectasis.
  • Aims to reduce lung flare-ups and improve breathing.
  • Involves using a nebulizer twice daily for at least 24 weeks.
  • Some participants get the real medicine, some get a dummy medicine (placebo).
  • Regular clinic visits for monitoring and tests.
  • Could help improve understanding and treatment of bronchiectasis.

¿Quién puede ser elegible?

To join this study, you need to be an adult between 18 and 80 years old with a diagnosis of non-cystic fibrosis bronchiectasis. Your diagnosis needs to be confirmed by a chest CT scan, and you should have experienced at least one lung flare-up requiring antibiotics or antivirals in the past year. You also need to produce mucus regularly and be able to provide a sample during your initial visit.

There are also some important rules about contraception for both men and women to ensure safety during the study and for 30 days afterwards. You'll need to be able to use the nebulizer correctly and perform some breathing tests. The doctors will check all these things to make sure the study is right for you, and that you're right for the study.

However, you cannot take part if you have other main lung conditions like COPD or asthma, or if your bronchiectasis is caused by cystic fibrosis or certain immune system problems. Current smokers cannot participate. These rules are in place to ensure the study focuses on the specific type of bronchiectasis we're investigating and to keep all participants safe.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes entre 18 y 80 años?
  2. Do you have non-cystic fibrosis bronchiectasis confirmed by a scan?
  3. Have you had a lung infection requiring antibiotics/antivirals in the last year?
  4. Do you regularly produce mucus?
  5. Are you a non-smoker?
  6. Are you able to use a nebulizer and do breathing tests?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll be given either the study medicine, ensifentrine, or a placebo (a dummy medicine). You won't know which one you're receiving, and neither will the study team. Both will be taken using a nebulizer, which turns the medicine into a fine mist for you to breathe in, twice a day.

The treatment period will last for at least 24 weeks, but could be up to 52 weeks. Over this time, you'll have regular visits to the clinic so the team can monitor your health, check your symptoms, perform breathing tests, and see how you're responding to the treatment. You'll also provide mucus samples. These visits are important for gathering all the necessary information about the medicine's effects. Your overall participation in the study, including follow-up, will be determined by the study's progress and when all participants have completed at least 24 weeks of treatment.

Riesgos y beneficios potenciales

Taking part in a study like this might offer a potential benefit of receiving a new medicine that could improve your bronchiectasis symptoms, reduce flare-ups, and enhance your quality of life. However, as with any new medicine, there could be side effects or risks that we don't fully know yet. You may also receive the placebo, meaning you wouldn't get the active medicine's potential benefits. You will continue to receive your usual care, but there's no guarantee the study medicine will help you personally. You are entirely free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (51)

  • Kirklin Clinic of UAB Hospital
    Código postal verificado
    Birmingham, United States· Reclutamiento
  • So Cal Institute for Respiratory Diseases, Inc.
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • University of California Davis Medical Center
    Código postal verificado
    Sacramento, United States· Reclutamiento
  • National Jewish Health Main Campus
    Código postal verificado
    Denver, Estados Unidos· Reclutamiento
  • MedStar Georgetown University Hospital
    Código postal verificado
    Washington D.C., Estados Unidos· Reclutamiento
  • University of Miami
    Código postal verificado
    Miami, United States· Reclutamiento
  • Emory University at Saint Joseph Pulmonary Clinic
    Código postal verificado
    Atlanta, Estados Unidos· Reclutamiento
  • Augusta University
    Código postal verificado
    Augusta, United States· Reclutamiento
  • ASHA Clinical Research
    Código postal verificado
    Hammond, United States· Reclutamiento
  • University of Iowa
    Código postal verificado
    Iowa City, Estados Unidos· Reclutamiento
  • University of Kansas Medical Center-Kansas City
    Código postal verificado
    Kansas City, Estados Unidos· Reclutamiento
  • Massachusetts General Hospital- 55 Fruit St
    Código postal verificado
    Boston, Estados Unidos· Reclutamiento

Preguntas comunes

What is a nebulizer?

A nebulizer is a machine that turns liquid medicine into a fine mist that you breathe in through a mask or mouthpiece, helping the medicine get deep into your lungs.

¿Qué es un placebo?

A placebo is a 'dummy' medicine that looks exactly like the real medicine but contains no active drug. It helps researchers understand if the new medicine is truly working better than no treatment at all.

What does 'double-blind' mean?

Double-blind means that neither you nor the doctors treating you will know whether you are receiving the real medicine or the placebo. This helps prevent any bias in the study results.

¿Cuánto tiempo estaré en el estudio?

You will be taking the study medicine for at least 24 weeks, and potentially up to 52 weeks, depending on the study's overall timeline.

Will I still receive my usual treatment?

Yes, you will continue to receive your standard medical care for bronchiectasis while participating in this study.

Cómo obtener más información

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway Toll Free Number

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bron…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.